Offices of the CIGB | |
Research institute overview | |
---|---|
Formed | July 1, 1985 |
Jurisdiction | Cuba |
Headquarters | Avenida 31 No. 15802,
Havana,
Cuba 23°04′26″N 82°27′08″W / 23.0738°N 82.4523°W |
Website |
www |
The Center for Genetic Engineering and Biotechnology ( Spanish: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba.
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World. [1]: 132 Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy. [1]: 132 Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB. [1]: 132
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers. [2] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers. [2]
As of 2017, CIGB had 1,600 employees and sold 21 products internationally. [1]: 138
As of 2020, CIGB had two joint ventures with China. [1]: 143
It is responsible for creating the Abdala vaccine. [3] [4] [5]
The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials. [6]